Kumanishi, Ryosuke
Kadowaki, Shigenori http://orcid.org/0000-0001-9923-5309
Mitani, Seiichiro
Matsushima, Tomohiro
Ogata, Takatsugu
Narita, Yukiya
Masuishi, Toshiki
Bando, Hideaki
Tajika, Masahiro
Yasui, Hisateru
Hara, Hiroki
Muro, Kei
Article History
Received: 4 December 2022
Accepted: 16 March 2023
First Online: 21 March 2023
Declarations
:
: Shigenori Kadowaki has received grants and personal fees from Ono Pharmaceutical Co., Ltd., Daiichi Sankyo, Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., MSD K.K.; grants from Janssen Pharmaceutical K.K., Nobelpharma Co., Ltd.; and personal fees from Bristol-Myers Squibb K.K., Bayer Yakuhin, Ltd., Eisai Co., Ltd., and Merck KGaA. Seiichiro Mitani has received grants from Taiho Pharmaceutical Co., Ltd. Yukiya Narita has received grants and personal fees from Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K.. Toshiki Masuishi has received grants and personal fees from Ono Pharmaceutical Co., Ltd. and received personal fees from Yakult Honsha. Hisateru Yasui has received grants from Ono Pharmaceutical Co., Ltd. and received personal fees from Bristol-Myers Squibb K.K. and Yakult Honsha. Hiroki Hara has provided an advisory role for Bristol-Myers Squibb K.K., Boehringer Ingelheim, Daiichi Sankyo, Dainippon Sumitomo, MSD K.K., and Ono Pharmaceutical Co., Ltd.; received grants from Amgen, Astellas, AstraZeneca K.K., Bayer Yakuhin, Ltd., BeiGene, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Janssen Pharmaceutical K.K., MSD K.K., and Ono Pharmaceutical Co., Ltd.; and received honoraria from Asahi Kasei, Bayer Yakuhin, Ltd., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Eli Lily and Company, Merck Biopharma, MSD K.K., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company. Kei Muro has received grants and personal fees from Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K.. The other authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: This study was approved by the Institutional Review Boards of the Aichi Cancer Center Hospital, Saitama Cancer Center, and Kobe City Medical Center General Hospital.